Newron Pharmaceuticals SpA (SWX:NWRN, ETR:NP5) CEO Stefan Weber speaks to Proactive's Thomas Warner about what the investors can expect from Newron during the coming months, including some fresh data from its ongoing evenamide trial.
Weber says that data up to this point has showed "unseen and unheard of" results for managing treatment-resistant schizophrenia cases.